CLINICAL TRIALS
The clinical experience and well-being of the patient are central to our drug discovery effort.
Narazaciclib (ON 123300) in Patients with Advanced Solid Tumors
Phase 1 in US (NCT04739293)
This is an exploratory Phase 1 study to assess the safety, tolerability, and pharmacokinetics of narazaciclib (ON 123300) capsules administered orally as escalating daily doses in patients with advanced cancer relapsed or refractory to at least one (1) prior line of therapy.
Status: Recruiting
Sponsor:
Onconova Therapeutics, Inc.
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
Phase 1/2a (NCT04263090)
This is an open-label, Phase 1/2a study incorporating a dose-escalating stage followed by a dose-expansion stage to study the combination of rigosertib and nivolumab in metastatic Kirsten rat sarcoma positive (KRAS+) lung adenocarcinoma patients who have progressed on standard first line treatment.
Status: Recruiting
Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborators:
Bristol-Myers Squibb
Onconova Therapeutics, Inc.
Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC
Phase 1 (NCT04177498)
This is a Phase 1 open study to assess efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB)-associated locally advanced/metastatic squamous cell carcinoma (SCC).
Status: Recruiting
Sponsor:
Thomas Jefferson University
Collaborator:
Onconova Therapeutics, Inc.
Rigosertib in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma
Phase 2 in Austria and England
This is a Phase 2 open study to assess efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB)-associated locally advanced/metastatic squamous cell carcinoma (SCC).
Status: Recruiting
Sponsor:
Prof. Johann W. Bauer MD
Collaborators:
DEBRA International
Onconova Therapeutics, Inc.
Narazaciclib (ON 123300) in Patients with Advanced Solid Tumors
Phase 1 in China
This is an open-label, dose-escalating Phase 1 study to study the safety and tolerability of narazaciclib (ON 123300) in patients with advanced solid tumors who have failed on prior therapies. An expansion cohort of breast and lung cancer patients will be enrolled at the recommended Phase 2 dose.
Status: Recruiting
Sponsor:
HanX BioPharmaceuticals
Collaborators:
Onconova Therapeutics, Inc.
